Nurse Practitioner · Cheshire, CT
NPI
1669131116
Since 2021
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
280 S Main St Ste 102
Cheshire, CT, 06410
Phone (860) 870-6385
Groups this clinician bills Medicare through
Medicare paid, 2024
$61K
685 services
Medicare patients, 2024
336
Average age 75
Drug cost, 2024
$2.7M
4,357 prescriptions
Company payments, 2025
$40.73
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anna Dzilenski was code 99215 (office e&m - established), 330 times for 239 patients. In total Anna Dzilenski billed 685 services in 10 codes, and Medicare paid $61K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 330 | 239 | $108.53 | $36K |
| 99308 SNF E&M | Facility | 134 | 34 | $51.96 | $6,963 |
| 99309 SNF E&M | Facility | 72 | 22 | $75.09 | $5,406 |
| 99214 Office E&M - Established | Office | 31 | 29 | $69.97 | $2,169 |
| 99305 SNF E&M | Facility | 29 | 24 | $92.69 | $2,688 |
| 99305 SNF E&M | Office | 27 | 25 | $92.69 | $2,503 |
| 99306 SNF E&M | Facility | 21 | 21 | $126.41 | $2,655 |
By year: 2022 $45K for 356 services; 2023 $62K for 557 services; 2024 $61K for 685 services.
Medicare prescription drug claims, 2024
In 2024, the drug Anna Dzilenski prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 729 prescriptions and refills. In total Anna Dzilenski wrote 4,357 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 729 | 1,818 | 234 | $29K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 322 | 859 | 108 | $14K |
| Rytary Carbidopa/Levodopa | 232 | 433 | 53 | $349K |
| Gabapentin Generic | 223 | 455 | 73 | $5,346 |
| Clonazepam Generic | 163 | 217 | 44 | $864 |
| Ongentys Opicapone | 137 | 169 | 30 | $112K |
| Primidone Generic | 136 | 333 | 38 | $2,986 |
| Rivastigmine Rivastigmine Tartrate | 118 | 224 | 32 | $5,790 |
| Nuplazid Pimavanserin Tartrate | 113 | 115 | 17 | $569K |
| Amantadine Amantadine Hcl | 97 | 204 | 37 | $5,840 |
| Horizant Gabapentin Enacarbil | 83 | 137 | 12 | $95K |
| Quetiapine Fumarate Generic | 79 | 164 | 17 | $1,072 |
| Trazodone Hcl Generic | 75 | 147 | 22 | $662 |
| Gocovri Amantadine Hcl | 74 | 120 | 17 | $321K |
| Escitalopram Oxalate Generic | 72 | 162 | 26 | $708 |
Brand drugs: 1,057 claims; generic drugs: 3,300 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anna Dzilenski $40.73 ($40.73 in general payments such as food, travel and fees) from 2 companies. The largest payer was Abbvie Inc. with $20.7.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.